Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, a treatment regimen combining cyproterone acetate and ethinyl estradiol significantly improved acne and seborrhoea in most women after three months, but had varied effects on hirsutism and alopecia.

This review discusses the mechanisms linking obesity and polycystic ovary syndrome and explores potential management options, but it presents no original research findings.

This review examines the epidemiology, pathophysiology, diagnosis, and management strategies for non-classic congenital hyperplasia due to 21-hydroxylase deficiency, and provides evidence-based recommendations for its treatment and genetic counseling.

Treating sleep apnea in young obese women with PCOS can improve heart health and insulin sensitivity.

In this study, cyproterone acetate at 2 mg daily was found to be as effective as higher doses in reducing hair growth for hirsute women over 12 months.

This review discusses the multi-system impacts of polycystic ovary syndrome and explores evaluation and treatment strategies, but it reports no new research findings.

This study found that high doses of cyproterone acetate were associated with an increased risk of meningioma, especially with exposure longer than one year.

This study found that treatment with cyproterone acetate and ethinyl oestradiol increased hair density in women with diffuse androgen-dependent alopecia, particularly when serum ferritin levels were above 40 μg/l.

This study concluded that finasteride, cyproterone acetate, and flutamide were similarly effective at reducing hirsutism in women, though they acted through different mechanisms.

In this study, low doses of cyproterone acetate with ethinylestradiol were as effective as low-dose flutamide in reducing acne severity in hyperandrogenic women, while finasteride was less effective.

This study found that the oral contraceptive containing drospirenone (EE/DRSP) was as effective as EE/CPA in reducing acne lesions, sebum production, and hair growth in women with acne.

This study found that both cyproterone acetate and spironolactone effectively reduced hair diameter and plasma testosterone levels in hirsute women, with no significant differences between the two treatments.

In this study, cyproterone acetate combined with estradiol dramatically improved hirsutism symptoms and significantly reduced plasma testosterone and androstenedione levels in patients over periods of up to three years.

This study found a strong dose-related increase in the risk of intracranial meningiomas associated with high doses of cyproterone acetate, with some reduction in risk after stopping the treatment.

Antiandrogens, particularly flutamide and CPA, are most effective for treating hirsutism, with long-term use needed for best results.

This study found that liarozole is more effective than cyproterone acetate for improving PSA response and survival in metastatic prostate cancer after first-line endocrine therapy, while maintaining quality of life.

This study found that both a high dose of CPA and GnRHa are effective for treating hirsutism in hyperandrogenic women, but GnRHa with add-back therapy may lead to a longer remission period.

This study found that combining cyproterone acetate with testosterone enanthate was highly effective in suppressing spermatogenesis, suggesting potential as a reversible male contraceptive method.

This review examines androgen status in male and female obesity and its influence on the metabolic syndrome, but reports no new clinical results.

This study found that both finasteride and a regimen of cyproterone acetate plus ethinyl estradiol effectively reduced hirsutism in women, with similar results despite differing hormonal effects.

This abstract reviews the use and effects of various antiandrogens, finding clinical benefits in treating hyperandrogenism in women and improvements in urinary symptoms or cancer management in men, but it reports no new clinical results.

This report describes a case of meningioma in a transwoman treated long-term with estradiol and cyproterone acetate, suggesting possible concern over female sex steroids and meningioma risk.

This review found limited evidence on the effectiveness of different antiandrogens for feminization in transgender women, suggesting cyproterone acetate, leuprolide, and medroxyprogesterone acetate may better suppress testosterone than spironolactone or estradiol alone.

This article reviews the use of cyproterone acetate for conditions like prostate cancer and sexual disorders, highlighting its effects on libido but reporting no new specific trial results.

This review discusses treatment options for hirsutism in women of childbearing age, focusing on the use of contraceptives, CPA, spironolactone, and third-line therapies, and reports no clinical results.

This article reviews the discovery and various physiological effects of cyproterone acetate, reporting its established indications for several androgen-driven conditions but providing no new clinical data.

This study suggests that Aldactone may be more effective than Diane in reducing hair growth, despite having minimal impact on hormone levels.

This study reported that women with Polycystic Ovary Syndrome have higher rates of clinically significant insomnia and excessive daytime sleepiness than women without the condition, highlighting the need for sleep disorder screening in this population.

This study reported that 44% of hirsute women undergoing cyproterone acetate treatment experienced impaired sexual enjoyment, highlighting the need to inform patients about potential side effects.

This review discusses treatments for female acne, highlighting the effectiveness of low-dose oral contraceptives and noting their similar side effects to placebo; it reports no new clinical results.